The potential of mRNA vaccines was established during the COVID-19 pandemic. Now, a new wave of candidates could soon hit the ...

R&D Day, Moderna MRNA announcedseveral updates about the advancements in its pipeline and its business outlook for the next ...

Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, ...

Primrose Bio, a San Diego biotech company, has begun a partnership to jointly develop and market products for mRNA medicines.

Moderna will slash five clinical programmes but says it remains on track for ten product approvals in the next three years.

Analysts expressed skepticism about plans detailed by Moderna’s R&D chief Stephen Hoge to trim research spending in ...

In a report released today, Edward Tenthoff from Piper Sandler maintained a Buy rating on Moderna (MRNA – Research Report), with a price ...

Moderna shares have dropped by over -41.67% since I last covered them over the summer. See why I continue to rate MRNA stock ...

With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its ...

Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and ...